DAFTAR PUSTAKA

1. Gudjonsson JE, Elder JT. Psoriasis. Dalam: Wolff K, Goldsmith

LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editor.
Fitzpatricks Dermatology in General Medicine. Edisi ke-7. New
York. McGraw-Hill;2008. h.169-193.
2. Langley R, Krueger G, Griffiths C. Psoriasis: epidemiology,
clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18ii23.
3. Neimann A, Porter S, Gelfand J. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006;1(1), 63-75.
4. Damasiewicz A, Kuda B. Hormonal factors in etiopathogenesis of
psoriasis. Pol Merkur Lekarski. 2007;22(127):75-8.
5. Foitzik K, Langan E, Paus R. Prolactin and the skin: A
dermatological perspective on an ancient pleiotropic peptide
hormone. Journal of investigative dermatology 2009;129:1071-87.
6. Guyton A, Hall J. Hormon-hormon hipofisis dan pengaturannya
oleh hipotalamus. Buku Ajar Fisiologi Kedokteran. Edisi ke-11.
Indonesia. EGC;2006. h.964-991.
7. Freeman E, Kanyicska B, Lerant A. Prolactin: structure, function,
and regulation of secretion. Physiological reviews 2000;80:4.
8. Yuan L, Lee Y. Prolactin modulation of immune and inflammatory
response. Endocrinology 2002;57:435-55.
9. Weber G, Neidhardt M, Frey H, Galle K, Geiger A. Treatment of
psoriasis with bromocriptin. Arch Dermatol Res. 1981;271:4379
10. Dunna SF, Finlay AY. Psoriasis, improvement during and
worsening after pregnancy. Br J Dermatol.1989;120:584
11. Giasuddin AS, El-Sherif AI, El-Ojali SI. Prolactin: does it have a
role in the pathogenesis of psoriasis?. Dermatology 1998;197:119
22
12. Azzizadeh M, Malek M, Amiri M. Does prolactin indicate severity
of psoriasis?. Iranian journal of dermatology 2009;12:3.
13. Dilme E, Martin G, Regana M. Serum prolactin levels ini psoriasis
and correlation with cutaneous disease activity. Clinical and
experimental dermatology 2010;36:29-32.
14. Sanchez RM, Umbert MP.
Psoriasis in association with
prolactinoma: three cases. Br J Dermatol. 2000;143:8647
15. Gorpeligolu C, Gungor E, Alli N. Is prolactin involved in
etiopathogenesis of psoriasis? J Eur Acad Dermatol Venereol.
2008;22:1135-6.
16. Das R, Jain A, Ramesh V. Current concepts in pathogenesis of
psoriasis. Indian J Dermatol. 2009;54(1):7-12.
17. Blauvelt A. New concept in the pathogenesis and treatment of
psoriasis: key roles for
IL-23, IL-17A and TGF-1. Expert
Rev. Dermatol. 2007;2(1), 69-78.

Universitas Sumatera Utara

18. Bettina M, Vavricka P, Guitart J. Diagnostic evaluation. Psoriatis

and Psoriatic Arthritis- An Integrated Approach. Edisi ke-1. New
York. Springer;2005. h.83-91.
19. Lisi P. Differential diagnosis of psoriasis. Reumatismo
2007;59:5660.
20. Lionel F. Differential diagnosis. An Atlas of Psoriasis. Edisi ke-2.
London. Taylor & Francis;2004. h.67-69.
21. Meier M, Sheth P. Clinical spectrum and severity of psoriasis. Curr
Probl Dermatol. Basel. 2009;38:120.
22. Feldman S, Krueger G. Psoriasis assesment tools in clinical trial.
Ann Rheum. Dis. 2005;64:ii65-ii68.
23. Kenneth B. Clinical outcome measurements. Psoriatis and Psoriatic
Arthritis- An Integrated Approach. Edisi ke-1. New York.
Springer;2005. h.125-128.
24. Bonifati C, Berardesca E. Clinical outcome measures of psoriasis.
Reumatismo 2007;59 :64-67.
25. Traub M, Marshall K. Psoriasis pathophysiology, conventional and
alternative approaches to treatment. Alternative Medicine Review
2007;12:319-30.
26. Reich K, Mrowietz U. Treatment goal in psoriasis. JDDG.
2007;5:566574.
27. Sullivan J. Treatment for severe psoriasis. Aust Prescr.
2009;32:1418.
28. Harvey J, Guyda, Friesen H. Serum prolactin levels in humans
from birth to adult life. Pediat. Res.1973;7:534-40.
29. Frantz AG. Prolactin. N Engl J Med. 1978;298: 201207.
30. Franklin Scientific Projects Ltd. Normal and pathological prolactin
levels. Clear Perspectives 1996;3:1-4.
31. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine
circuitry of the brainskin connection. Trends Immunol.
2006;27:329.
32. Girolomoni G, Phillips JT, Bergstresser PR. Prolactin stimulates
proliferation of cultured human keratinocytes. J Invest Dermatol.
1993;101:2759.
33. Yu-Lee L. Stimulation of interferon regulatory factor-1 by
prolactin. Lupus 2001;10:6919.
34. De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A.
Prolactin and autoimmunity. Pituitary 2005;8:2530.
35. Biswas R, Roy T, Chattopadhyay U. Prolactin induced reversal of
glucocorticoid mediated apoptosis of immature cortical thymocytes
is abrogated by induction of tumor. J Neuroimmunol.
2006;171:12034.
36. Carreno PC, Jimenez E, Sacedon R, Vicente A, Zapata AG.
Prolactin stimulates maturation and function of rat thymic dendritic
cells. J Neuroimmunol. 2004;153:8390.
37. Matera L, Mori M, Galetto A. Effect of prolactin on the antigen
presenting function of monocyte-derived dendritic cells. Lupus
2001;10:72834.

Universitas Sumatera Utara

38. Sun R, Li AL, Wei HM, Tian ZG. Expression of prolactin receptor
and response to prolactin stimulation of human NK cell lines. Cell
Res. 2004;14:6773
39. Malaguarnera L, Imbesi R, Di Rosa M, Scuto A et al. Action of
prolactin, IFN-gamma, TNF-alpha and LPS on heme oxygenase-1
expression and VEGF release in human monocytes/macrophages.
Int Immunopharmacol. 2005;5:145869.
40. Kanda N, Watanabe S. Prolactin enhances interferon- induced
production of CXCL9, CXCL10, and CXCL11. Endocrinology
2007;148:231725.
41. Kanda N, Shibata S, Tada Y et al. Prolactin enhances basal and IL17 induced CCL20 production by human keratinocytes. Eur J
Immunol. 2009;39(4):996-1006.
42. Murase J, Chan K, Garite T et al. Hormonal effect of psoriasis in
pregnancy and post partum. Arch Dermatol. 2005;141:601-606.
43. Raychaudhuri S, Navare T, Gross J et al. Clinical course of
psoriasis during pregnancy. International Journal of Dermatology
2003;42:518520.
44. Griffiths CE, Katsambas A, Dijkmans BA et al. Update on the use
of ciclosporin in immune-mediated dermatoses. Br J Dermatol.
2006;155:116.
45. Suite M. The epidemiology of psoriasis in a dermatology clinic in a
general hospital in port of Spain, Trinidad and Tobago, West
Indies. West Indian Med J. 2006;55(6):1.
46. Naldi L. Epidemiology of psoriasis.Curr Drug Target Inflamm
Allergy. 2004;3(2):121-8.
47. Fatani MI, Abdulghani MH, Al-Afif KA. Psoriasis in the eastern
saudi arabia. Saudi Med J. 2002;23(2):213-7.
48. Dogra S, Yadav S. Psoriasis in India: prevalence and pattern.
Indian J Dermatol Venereol Leprol 2010;76:595-60.
49. Mabuchi T, Yamaoka H, Kojima T et al. Psoriasis affects patient
quality of life more seriously in female than male in Japan. Tokai J
Exp Clin Med. 2012;37(3):84-8.
50. Gupta MA, Gupta KA. Age and gender differences in the impact of
psoriasis on quality of life. Int J Dermatol. 1995;34:700-703.
51. Jacobson CC, Kimball AB. Epidemiology. Dalam: Kenneth B,
editor. Psoriasis and Psoriatic Arthritis- An Integrated Approach.
Edisi ke-1. New York. Springer;2005. h.125-128.
52. Inerot A, Enerback C, Enlund et al. Collecting a set of psoriasis
family material through a patient organization; clinical
characterization and presence of additional disorders. BMC
Dermatology. 2005;5(10):1-8.

Universitas Sumatera Utara